Nanomedicine in cancer stem cell therapy: from fringe to forefront

被引：21

作者：

Tabassum, Nazish ^{[1
]}

Verma, Vinod ^{[1
]}

Kumar, Manoj ^{[2
]}

Kumar, Ashok ^{[3
]}

Singh, Birbal ^{[4
]}

机构：

[1] Univ Allahabad, Ctr Biotechnol, Nehru Sci Complex, Allahabad 211002, Uttar Pradesh, India

[2] ICMR, NIREH, Kamla Nehru Hosp Bldg, Bhopal, India

[3] MLK Post Grad Coll, Dept Zool, Balrampur, India

[4] Indian Vet Res Inst, Reg Stn, Palampur, Himachal Prades, India

来源：

CELL AND TISSUE RESEARCH | 2018年 / 374卷 / 03期

关键词：

Nanomedicine; Nanomaterials; Nanodevice; Cancer stem cells (CSCs); Drug delivery; TARGETED THERAPY; PHASE-I/II; IN-VITRO; REXIN-G; NANOPARTICLES; DRUG; COMBINATION; DELIVERY; DOXORUBICIN; PACLITAXEL;

D O I：

10.1007/s00441-018-2928-5

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Nanomedicine is the spin-off of modern medicine and nanotechnology and aims to prevent and treat diseases using nanoscale materials such as biocompatible nanoparticles and nanorobots. Targeted cellular and tissue-specific clinical applications with maximal therapeutic effects and insignificant side effects could be achieved by the pursuit of nanotechnology in medicine and healthcare regimen. The majority of conventional cancer therapies eliminate the cells of the tumor but not the cancer stem cells (CSCs). Conversely, the use of nanotechnology in CSC-based therapies is an emerging field of biomedical sciences. This article summarizes the recent trends and application of nanomedicine especially in CSC therapy along with its limitations.

引用

页码：427 / 438

页数：12

共 85 条

[1] Gold nanoparticles in theranostic oncology: current state-of-the-art [J].

Akhter, Sohail ;

Ahmad, Mohammad Zaki ;

Ahmad, Farhan Jalees ;

Storm, Gert ;

Kok, Robbert J. .

EXPERT OPINION ON DRUG DELIVERY, 2012, 9 (10) :1225-1243

[2] Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials [J].

Alberts, DS ;

Muggia, FM ;

Carmichael, J ;

Winer, EP ;

Jahanzeb, M ;

Venook, AP ;

Skubitz, KM ;

Rivera, E ;

Sparano, JA ;

Dibella, NJ ;

Stewart, SJ ;

Kavanagh, JJ ;

Gabizon, AA .

SEMINARS IN ONCOLOGY, 2004, 31 (06) :53-90

[3] Advantages of liposomal delivery systems for anthracyclines [J].

Allen, TM ;

Martin, FJ .

SEMINARS IN ONCOLOGY, 2004, 31 (06) :5-15

[4] Targeting cancer stem cells in the clinic: Current status and perspectives [J].

Annett, Stephanie ;

Robson, Tracy .

PHARMACOLOGY & THERAPEUTICS, 2018, 187 :13-30

[5]

[Anonymous], 2008, ASIAN J EXP SCI

[6]

Astruc D, 1996, CR ACAD SCI II B, V322, P757

[7] Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity [J].

Azad, Nilofer S. ;

Posadas, Edwin M. ;

Kwitkowski, Virginia E. ;

Steinberg, Seth M. ;

Jain, Lokesh ;

Annunziata, Christina M. ;

Minasian, Lori ;

Sarosy, Gisele ;

Kotz, Herbert L. ;

Premkumar, Ahalya ;

Cao, Liang ;

McNally, Deborah ;

Chow, Catherine ;

Chen, Helen X. ;

Wright, John J. ;

Kohn, Elise C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3709-3714

[8] Theranostic Nanoshells: From Probe Design to Imaging and Treatment of Cancer [J].

Bardhan, Rizia ;

Lal, Surbhi ;

Joshi, Amit ;

Halas, Naomi J. .

ACCOUNTS OF CHEMICAL RESEARCH, 2011, 44 (10) :936-946

[9] Doxil® - The first FDA-approved nano-drug: Lessons learned [J].

Barenholz, Yechezkel .

JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134

[10] Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma [J].

Benezra, Miriam ;

Penate-Medina, Oula ;

Zanzonico, Pat B. ;

Schaer, David ;

Ow, Hooisweng ;

Burns, Andrew ;

DeStanchina, Elisa ;

Longo, Valerie ;

Herz, Erik ;

Iyer, Srikant ;

Wolchok, Jedd ;

Larson, Steven M. ;

Wiesner, Ulrich ;

Bradbury, Michelle S. .

JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (07) :2768-2780

← 1 2 3 4 5 6 7 8 9 →